

PELA® STRATEGIC DIRECTIONS IN SYSTEM FORMULARY, DRUG POLICY, AND HIGH-COST DRUG MANAGEMENT

The ASHP Pharmacy Executive Leadership Alliance (PELA®) convened a virtual conference to discuss current strategies, challenges, and opportunities related to managing system-wide Pharmacy & Therapeutics (P&T) Committees including high-cost drugs and new cell and gene therapies.



4 TRENDS DRIVING THE PRESCRIPTION DRUG MARKET



1 ADVANCES IN MEDICATIONS AND THERAPIES 

2 RISING HEALTH CARE COSTS 

3 INNOVATIONS IN TECHNOLOGY 

4 SHIFTING DRUG ACCESS CHANNELS 

OPTIMIZING FORMULARY MANAGEMENT IN INTEGRATED DELIVERY NETWORKS



STAY FLEXIBLE AS PROCESSES EVOLVE

INVOLVE SPECIALISTS EARLY

EMBED DRUG POLICIES INTO CLINICAL DECISION SUPPORT TECH TOOLS

ENSURE CLEAR COMMUNICATION

PREPARE THOROUGHLY FOR COMPLEX TREATMENTS AND REVIEW OUTCOMES

VALIDATE ASSUMPTIONS AND ADAPT WHEN NEEDED

STRATEGIES TO IMPROVE DRUG MANAGEMENT AND COSTS IN HEALTH SYSTEMS



CREATE AND IMPLEMENT STRATEGIES TO MANAGE HIGH-COST TREATMENTS

UPDATE DRUG MANAGEMENT PLANS TO STAY CURRENT WITH MARKET TRENDS



EFFECTIVELY MANAGE THE PATIENT JOURNEY FOR HIGH-COST MEDICATIONS



COLLABORATE WITH PAYERS TO IMPROVE PATIENT ACCESS TO INNOVATIVE THERAPIES



ADJUST P&T COMMITTEE MEMBERS FOR BROADER ADVICE AND QUICKER DECISIONS

For more insights from the PELA® Strategic Directions in System Formulary, Drug Policy, and High-Cost Drug Management Conference visit

[ASHP.ORG/PELA](https://www.ashp.org/pela)